Coherence Neuro is developing a brain implant designed to detect electrical signals associated with tumors and, eventually, respond with mild stimulation. OpenAI’s venture capital arm and Peter Thiel’s Founders Fund are investing in the startup as part of a $45 million seed round, linking cancer research with a wider technology interest in brain data.
Reading signals linked to tumors
Coherence is building AI models to interpret subtle electrical activity associated with brain tumors. The company says it can already identify these signals in animals and use them to determine whether cancer is growing, shrinking, or recurring. It is now working to translate those findings into human research.
The approach differs from brain-computer interfaces focused on restoring function for people with paralysis. Coherence’s goal is to use neural data in cancer detection and treatment. The implant is designed both to record activity and to emit mild electrical stimulation intended to halt tumor growth.
The longer-term concept is a device that learns to recognize cancer-associated signals and provides treatment in real time. That remains a development goal, rather than an established clinical capability. The company says its next steps include research in people and, eventually, clinical trials.
Early human testing and next steps
This summer, Coherence briefly tested the implant’s recording ability in three people who were already having brain tumor removal surgery at the Royal Melbourne Hospital in Australia. The device remained in place for roughly 30 minutes before removal, providing an initial safety check.
The company is now testing both recording and stimulation in an additional seven patients. Coherence plans to use its new funding to launch a clinical trial involving long-term implantation in patients with glioblastoma, an aggressive type of brain cancer. It also wants to develop implants for cancers elsewhere in the body.
These steps reflect a progression from short-term recording during surgery toward longer-term use. The source describes the early test as an initial safety check; it does not establish that the implant can yet treat tumors in people. Further research will be needed to assess whether the signals can support reliable detection and whether stimulation can affect tumor growth.
Why AI investors are interested
Coherence’s CEO and cofounder Ben Woodington says brain-computer interface developers collect datasets too large for people to analyze on their own. AI models could help interpret raw neural signals and connect them with outcomes, whether those are tumor activity or actions such as moving a cursor or producing synthesized speech.
Woodington describes a “growing synergy” between AI labs and companies building brain-computer interfaces. In his view, brain data could help train models and improve treatments. The investment in Coherence fits into that broader interest, while the company’s specific aim is cancer detection and treatment.
OpenAI has also invested directly in Merge Labs, a brain-computer interface company cofounded by Sam Altman. Merge Labs is pursuing ultrasound technology to decode information from the brain. OpenAI said its investment reflected the view that these interfaces could offer people a natural way to interact with AI. Founders Fund has backed Neuralink and CTRL-labs, whose wristband translates neural signals from arm and hand movements and was acquired by Facebook in 2019.
Funding, data and the relationship with investors
Coherence says OpenAI will not have access to the brain or health data the startup generates. Woodington said there is no provision in the contracts or arrangements for sharing that information. That distinction matters because the investment arrives amid growing interest in turning neural data into a resource for AI research and applications.
OpenAI’s relationship with Merge Labs has been described differently: the company said it would collaborate with Merge Labs on scientific foundation models and other frontier tools. Coherence’s stated data arrangements, by contrast, do not give OpenAI access to its data.
For now, the investment backs a research path with several stages still ahead: interpreting signals in people, testing stimulation, and pursuing long-term implantation in a clinical trial. The project’s promise rests on whether neural signals can become useful indicators of tumor behavior and whether an implant can safely respond to them.